Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/155231
Title: Modular design of a hybrid hydrogel for protease-triggered enhancement of drug delivery to regulate TNF-α production by pro-inflammatory macrophages
Authors: Nguyen, Dang Tri
Soeranaya, Bob Hartadhi Tji
Truong, Thi Hong Anh
Dang, Tram Thuy
Keywords: Engineering::Bioengineering
Issue Date: 2020
Source: Nguyen, D. T., Soeranaya, B. H. T., Truong, T. H. A. & Dang, T. T. (2020). Modular design of a hybrid hydrogel for protease-triggered enhancement of drug delivery to regulate TNF-α production by pro-inflammatory macrophages. Acta Biomaterialia, 117, 167-179. https://dx.doi.org/10.1016/j.actbio.2020.09.026
Project: ARISE/2017/16
M4082061.120
M4081759.120
M4011637.120
H19/01/a0/HH9
Journal: Acta Biomaterialia
Abstract: Systemic drug administration has conventionally been prescribed to alleviate persistent local inflammation which is prevalent in chronic diseases. However, this approach is associated with drug-induced toxicity, particularly when the dosage exceeds that necessitated by pathological conditions of diseased tissues. Herein, we developed a modular hybrid hydrogel which could be triggered to release an anti-inflammatory drug upon exposure to elevated protease activity associated with inflammatory diseases. Modular design of the hybrid hydrogel enabled independent optimization of its protease-cleavable and drug-loaded subdomains to facilitate hydrogel formation, cleavability by matrix-metalloprotease-9 (MMP-9), and tuning drug release rate. In vitro study demonstrated the protease-triggered enhancement of drug release from the hybrid hydrogel system for effective inhibition of TNF-α production by pro-inflammatory macrophages and suggested its potential to mitigate drug-induced cytotoxicity. Using non-invasive imaging to monitor the activity of reactive oxygen species in biomaterial-induced host response, we confirmed that the hybrid hydrogel and its constituent materials did not induce adverse immune response after 5 days following their subcutaneous injection in immuno-competent mice. We subsequently incorporated this hybrid hydrogel onto a commercial wound dressing which could release the drug upon exposure to MMP-9. Together, our findings suggested that this hybrid hydrogel might be a versatile platform for on-demand drug delivery via either injectable or topical application to modulate inflammation in chronic diseases.
URI: https://hdl.handle.net/10356/155231
ISSN: 1742-7061
DOI: 10.1016/j.actbio.2020.09.026
Rights: © 2020 Acta Materialia Inc. All rights reserved. This paper was published by Elsevier Ltd in Acta Biomaterialia and is made available with permission of Acta Materialia Inc.
Fulltext Permission: embargo_20221207
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Journal Articles

Files in This Item:
File Description SizeFormat 
ACTBIO-S-20-01709 - accepted manuscript.pdf
  Until 2022-12-07
2.98 MBAdobe PDFUnder embargo until Dec 07, 2022

SCOPUSTM   
Citations 20

9
Updated on Nov 29, 2022

Web of ScienceTM
Citations 20

9
Updated on Nov 30, 2022

Page view(s)

64
Updated on Dec 1, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.